People planning on participating in the upcoming $6M placement?...

People planning on participating in the upcoming $6M placement?

Also interesting about asset divestment. Wonder what that could refer to??



The Directors believe that it is reasonably foreseeable that the Group will continue as a going concern and that it is appropriate to adopt
the going concern basis in the preparation of the financial report after consideration of the following factors:
• A share placement of $7.7 million completed with $4.3 million already received
• A loan of $5 million from a strategic investor, Star Bright Holding Ltd and associates (“Star Bright”, received in August 2018
resulting in the payout of the PFG Term Debt
• An intended rights issue targeting at least $6.0 million (before costs) net of Star Bright’s rights entitlement. The equivalent
quantum of Star Bright’s entitlement will be applied to reduce the new loan
• Positive net working capital and cash balances totalling $2,524,132
• Contract wins for the Infusion business
• Advanced negotiations to secure funding for Admedus Vaccines
• Potential divestment of assets
• Recently introduced product lines such as CardioCel® Neo, VascuCel®, and CardioCel® 3D that are at varying stages of
penetration in our existing markets
• New product lines to be launched such as CardioCel® 3D Stage 1 Arch, Half Pipe Conduit and Adult AV Leaflets that are at varying
stages of design development, regulatory clearance and user evaluation
• New markets for the Groups ADAPT® products including India, Australia, Philippines, Taiwan, Vietnam, Israel, Thailand, Mexico,
Japan and Spain
• New partnerships and alliances for ADAPT and TAVR products
• Monitoring, management and containment of operational costs, including R&D costs, and capital expenditures
• A remuneration review undertaken by the Company